BioCentury
ARTICLE | Clinical News

Warfarin: Phase III data

November 25, 2013 8:00 AM UTC

The double-blind, U.S. Phase III COAG trial in 1,015 patients initiating warfarin therapy with a target INR of 2-3 showed that an algorithm combining a patient's genetic data with clinical variables t...